Switch theme
Sign up to access all valuation multiples
Fangzhou Inc is a online chronic disease management platform in China. It has focus on chronic disease management to address the needs of patients with chronic diseases, such as hypertension, cardiovascular and respiratory chronic diseases. The company provide comprehensive medical services and online retail pharmacy services through Jianke Platform. The principal segment of the group are online retail pharmacy services, comprehensive medical services and customized content and marketing solutions. Key revenue is generated from Online retail pharmacy services.
2019
488
Last FY Revenue $346M
Last FY EBITDA -$106M
$665M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Fangzhou achieved revenue of $346M and an EBITDA of -$106M.
Fangzhou expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Fangzhou valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $346M | XXX | XXX | XXX |
| Gross Profit | XXX | $65.9M | XXX | XXX | XXX |
| Gross Margin | XXX | 19% | XXX | XXX | XXX |
| EBITDA | XXX | -$106M | XXX | XXX | XXX |
| EBITDA Margin | XXX | -31% | XXX | XXX | XXX |
| EBIT | XXX | -$95.6M | XXX | XXX | XXX |
| EBIT Margin | XXX | -28% | XXX | XXX | XXX |
| Net Profit | XXX | -$109M | XXX | XXX | XXX |
| Net Margin | XXX | -32% | XXX | XXX | XXX |
| Net Debt | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Fangzhou's stock price is HKD 4 (or $1).
Fangzhou has current market cap of HKD 5.4B (or $695M), and EV of HKD 5.2B (or $665M).
See Fangzhou trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $665M | $695M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Fangzhou has market cap of $695M and EV of $665M.
Fangzhou's trades at 1.9x EV/Revenue multiple, and -6.3x EV/EBITDA.
Equity research analysts estimate Fangzhou's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Fangzhou's P/E ratio is not available.
See valuation multiples for Fangzhou and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $695M | XXX | $695M | XXX | XXX | XXX |
| EV (current) | $665M | XXX | $665M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 1.9x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -6.3x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -7.0x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -6.4x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 333.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialFangzhou's revenue per employee in the last FY averaged $0.7M, while opex per employee averaged $0.3M for the same period.
Fangzhou's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Fangzhou's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Fangzhou and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -31% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.7M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 13% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 47% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| MedPlus India | XXX | XXX | XXX | XXX | XXX | XXX |
| SC Ropharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Pague Menos | XXX | XXX | XXX | XXX | XXX | XXX |
| Droga Raia | XXX | XXX | XXX | XXX | XXX | XXX |
| Redcare Pharmacy | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Fangzhou acquired XXX companies to date.
Last acquisition by Fangzhou was XXXXXXXX, XXXXX XXXXX XXXXXX . Fangzhou acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Fangzhou founded? | Fangzhou was founded in 2019. |
| Where is Fangzhou headquartered? | Fangzhou is headquartered in Hong Kong. |
| How many employees does Fangzhou have? | As of today, Fangzhou has 488 employees. |
| Is Fangzhou publicy listed? | Yes, Fangzhou is a public company listed on HKG. |
| What is the stock symbol of Fangzhou? | Fangzhou trades under 06086 ticker. |
| When did Fangzhou go public? | Fangzhou went public in 2024. |
| Who are competitors of Fangzhou? | Similar companies to Fangzhou include e.g. MedPlus India, SC Ropharma, Pague Menos, Droga Raia. |
| What is the current market cap of Fangzhou? | Fangzhou's current market cap is $695M |
| Is Fangzhou profitable? | Yes, Fangzhou is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
